Today, we announced that data from our Phase 2b TYDAL study of MAR001 will be presented in a late-breaking science session at @American_Heart #ScientificSessions26 this November. MAR001 is a potential first-in-class monoclonal antibody targeting ANGPTL4, a genetically validated target associated with triglyceride levels, adipose tissue function and cardiometabolic disease. Details: mareatx.com/press-releases/m…

We're excited to announce that we've entered into a definitive agreement with @Lisata_tx ($LSTA) to combine the companies in an all-stock transaction. The outcome will focus on advancing MAR001/005 and MAR002 through key clinical milestones, including the completion of an ongoing Phase 2b trial in patients with severe hypertriglyceridemia and a Phase 2 trial in patients with acromegaly. To support the acquisition, we secured an oversubscribed $225 million private placement from a syndicate of leading healthcare investors, which is expected to close concurrently. Details: mareatx.com/press-releases/l…

This weekend at #ENDO2026, we presented Phase 1 data for MAR002 in #acromegaly. The data demonstrates deep and durable IGF-1 suppression that could enable once every two-week dosing vs. the daily injections required today. We plan to initiate the Phase 2/3 study later this year. Full details: mareatx.com/press-releases/m…

Excited to be heading to #ENDO26, where we'll present data from our Phase 1 first-in-human study of MAR002, a first-in-class allosteric monoclonal antibody targeting the growth hormone receptor (GHR) for #acromegaly. Our previously announced top-line data showed robust and durable IGF-1 suppression, and we're on track to initiate a Phase 2/3 study later this year. Read the full release: mareatx.com/press-releases/m…

Rare diseases often carry effects far beyond what’s visible. In #acromegaly, delayed recognition and incomplete control can drive serious cardiovascular and metabolic complications over time. On #RareDiseaseDay, we recognize the patients and families navigating this reality. The responsibility we share as scientists and clinicians deepens our understanding of disease biology and will translate human genetics into improved outcomes for patients.

Did you know that in the U.S., someone dies from cardiovascular disease every 34 seconds? Heart disease and stroke remain the leading causes of death nationwide. This #AmericanHeartMonth is a reminder of why our work matters year-round – advancing next-generation therapies for people living with cardioendocrine diseases. Small steps and scientific progress together can help keep #ourhearts going.

Atherosclerotic cardiovascular disease (ASCVD) is the most prevalent and leading cause of death among cardiovascular diseases. While LDL-C-lowering therapies have transformed care, many patients with established ASCVD continue to have residual cardiovascular risk, particularly those with elevated triglycerides and remnant cholesterol. #OurHearts are committed to advancing the next frontier in cardioendocrine diseases to develop more precise, targeted therapies that address the root causes of these conditions.

#OurHearts are committed to patients. In honor of #AmericanHeartMonth, we’re standing with patients and communities that are facing heart diseases every day, and are driven by the shared commitment to develop meaningful therapies to address the risks of ASCVD.

Diving in with @Ky_Lahucik at @Endpts, CEO Josh Lehrer & CSO @ethanjweiss share how MAR002 emerged as a key program. The piece highlights our newly released positive Ph1 acromegaly data, upcoming Ph 2/3 plans, & broader pipeline momentum as we head into a pivotal year. Read more below. endpoints.news/marea-takes-d…

Today, we shared positive topline Phase 1 results for MAR002 in #acromegaly, demonstrating clear proof-of-mechanism and supporting its first-in-class potential. We also highlighted key 2026 milestones across our pipeline, including full enrollment of the Phase 2b TYDAL-TIMI 78 study of MAR001 in cardiometabolic disease. Hear more from CEO Josh Lehrer below. Read the full announcement: mareatx.com/press-releases/m…

We’re looking ahead to #JPM26 next week. Marea CEO Josh Lehrer will share updates on our pipeline, including MAR001, a first-in-class ANGPTL4 antibody in the Phase 2b TYDAL-TIMI 78 study for adults at risk for ASCVD, and MAR002, a first-in-class growth hormone receptor antibody in Phase 1 development for acromegaly. Learn more: mareatx.com/press-releases/m…

We were honored to welcome Jill Sisco, acromegaly patient advocate & President of @AcroCommunity, to our recent town hall. Jill shared her lived experience with acromegaly & highlighted how the organization helps patients & caregivers better understand the disease & navigate diagnosis & treatment. Her perspective reinforced why patient voices matter as we advance our MAR002 program for #acromegaly. Thank you, Jill, for sharing your story & for your leadership, which supports our mission to translate human genetics into meaningful medicines grounded in real patient needs.

Acromegaly often develops slowly & can take 5–10 years to diagnose, leading to serious complications if left untreated. On #AcromegalyAwarenessDay, we’re working to close the diagnostic gap through science that could transform endocrine care.

Marea leadership will attend several investor conferences through the end of the year. Excited to share how our science & strategy are shaping the future of #cardiometabolic and #endocrine care.

We’ve gained promising momentum for MAR001 in cardiovascular disease. Our Phase 2a data show meaningful reductions in triglycerides & remnant cholesterol with a favorable safety profile, and our TYDAL-TIMI 78 Phase 2b trial is now enrolling. Proud to serve as an educational sponsor of this event. Watch the full talk here (login required). triglycerideforum.org/expert…

At Marea, we’re tackling residual #cardiovascular risk by targeting ANGPTL4. MAR001 boosts LPL activity to lower triglycerides & remnant cholesterol, key drivers of #ASCVD not addressed by current therapies. We’re proud to support the @TriglycerideF, where Dr. Sander Kersten shared new insights. (login required). triglycerideforum.org/expert…

#CardiovascularDisease (CVD) claims 20.5M+ lives each year, making it the leading cause of death in the U.S.We joined @American_Heart at the 2025 Bay Area Heart Walk and on #WorldHeartDay, we stand with communities worldwide to raise awareness, fund research, and promote prevention. At Marea, we’re committed to learning more about restoring balance in the body’s vital processes to fight heart disease. We’re honored to stand alongside so many others in this fight. #DontSkipABeat ❤️

Last week, Co-founder/CSO @ethanjweiss & our Head of Genetics & Program Team Lead traveled to Lisbon to attend the 17th Consensus Conference on Acromegaly, where they presented highlights on MAR002, our next-gen GHR antagonist for the treatment of #acromegaly. We’re proud to have joined experts from across the globe with a shared mission to improve the lives of people living with acromegaly through better treatment options.